Boardroom Alpha
Meeting calendar
ALEC · Annual meeting · Wednesday, June 17, 2026

Alector Inc

3 nominees · 3 ballot items.

Three proposals: election of three Class II directors (Elizabeth Garofalo, M.D.; Errol De Souza, Ph.D.; Kristine Yaffe, M.D.), ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, and a non-binding advisory vote to approve the compensation of the named executive officers (say-on-pay).

Market cap
$229M
1Y TSR
-18.9%
Board grade
C-
Record date
Apr 20, 2026
Filing
DEF 14A
Meeting concluded · Jun 17, 2026

Follow how the vote landed and what changed on Alector Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    To elect three Class II directors—Elizabeth Garofalo, M.D.; Errol De Souza, Ph.D.; and Kristine Yaffe, M.D.—to serve three-year terms until the 2029 annual meeting and until their successors are duly elected and qualified.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    To ratify the Audit Committee’s appointment of Ernst & Young LLP as Alector’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay

    ManagementBoard: FOR

    A non-binding, advisory vote to approve the compensation paid to the Company’s named executive officers as disclosed in the proxy statement, including compensation tables and related narrative.

    More detail

    This proposal requests a non‑binding shareholder endorsement of the Company’s disclosed executive compensation program for the named executive officers. Management seeks approval to confirm that its pay practices — a mix of base salary, annual incentive bonuses tied to corporate and individual goals, and long‑term equity (including reintroduced stock options and RSUs) — are aligned with stockholder interests and effective for retention. The Compensation Committee engaged an independent advisor (Pearl Meyer) and recalibrated the peer group to better reflect the Company’s stage and profile; equity awards in 2025 included both options and RSUs and supplemental November grants to address retention concerns. For 2025 the corporate bonus pool was funded at 80% of target, and bonus payouts were delivered 50% cash and 50% RSUs vesting over one year to support cost containment while preserving retention incentives. Management emphasizes pay‑for‑performance design, clawback policy, anti‑hedging and anti‑pledging rules, and limits on excessive perquisites and change‑in‑control single‑trigger payments to mitigate risk. The vote is advisory only, but historically the Company’s say‑on‑pay received overwhelming support (>98% in 2025), and the Board intends to consider voting outcomes in future compensation decisions. The Board’s recommendation in favor rests on the view that the program balances competitive pay for key talent, performance alignment, and governance safeguards, while addressing company‑specific retention and stage‑of‑development considerations. The Compensation Committee retains discretion over final payouts and may adjust awards to reflect company performance and strategic needs. Overall, the proposal is a routine annual advisory vote meant to give stockholders a voice on executive pay and to provide feedback to the Board and Compensation Committee.

Director elections

Nominees on the ballot3

Independent
Tenure on this board
4.9 yrs
Also a director at
Acadia Pharmaceuticals Inc (ACAD)Xenon Pharmaceuticals Inc (XENE)
Independent
Tenure on this board
2.4 yrs
Also a director at
Cyclerion Therapeutics Inc (CYCN)
Ownership

Top institutional holders10

Latest 13F quarter
1TCG Crossover Management, LLC9.0%10,000,000$20M
2ACADIAN ASSET MANAGEMENT LLC4.0%4,414,345$9M
3Nantahala Capital Management, LLC3.9%4,318,109$9M
4VANGUARD CAPITAL MANAGEMENT LLC3.6%4,009,340$8M
5BlackRock, Inc.3.5%3,919,590$8M
6Kynam Capital Management, LP3.4%3,808,494$8M
7Merck Co., Inc.3.2%3,545,719$7M
8BALYASNY ASSET MANAGEMENT L.P.2.9%3,247,426$7M
9683 Capital Management, LLC2.9%3,200,000$6M
10BlackRock, Inc.2.6%2,905,617$6M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Alector Inc 2026 annual meeting?
Alector Inc (ALEC) holds its 2026 annual shareholder meeting on Wednesday, June 17, 2026.
What is the record date for the Alector Inc 2026 meeting?
The record date for the Alector Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Alector Inc's 2026 meeting?
The board is presenting 3 director nominees at the Alector Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Alector Inc 2026 meeting?
Shareholders will vote on 3 proposals at the Alector Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer